A Study of Olanzapine in Patients With Acute Agitation

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT02512705` - Medical Monitoring for Agitated Patients Pilot RCT - Medical Monitoring	N/A
Terminated	`NCT03246620` - Oral Olanzapine Versus Haloperidol or Diazepam	Phase 4
Completed	`NCT03624322` - Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101	Phase 1

See also

Status

Clinical Trial

Phase

Not yet recruiting

NCT02512705 - Medical Monitoring for Agitated Patients Pilot RCT - Medical Monitoring

N/A

Terminated

NCT03246620 - Oral Olanzapine Versus Haloperidol or Diazepam

Phase 4

Completed

NCT03624322 - Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05803642
Study type	Interventional
Source	Qilu Pharmaceutical Co., Ltd.
Contact	Gang Wang, PhD
Phone	010-58303236
Email	adwanggang@163.com
Status	Not yet recruiting
Phase	Phase 3
Start date	March 28, 2023
Completion date	July 2, 2024

A Study of Olanzapine in Patients With Acute Agitation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms